Citations

Clear

585 citation(s) found for "Tran, Ha".

Use of Contrast‐Enhanced Ultrasound in Genital Lymphedema: A Report of Three Cases
Rios‐Sanchez, Maria V. , Aristizábal, Alejandra , Bruces‐Molina, Carlos, Lee, Christine U. , Tran, Nho V. , Fahradyan, Vahe , Bruces-Molina, Carlos, Fahradyan, Vahe , Bustos, Samyd S.

Mayo Clinic

Microsurgery | September 4, 2025 | Volume: 45 | Issue: 6 | Pages: No page available

10.1002/micr.70114 | PMID 40905543 Get It

ABSTRACT Genital lymphedema presents significant challenges in surgical management, with limited effective interventions. This case report explores the use of contrast‐enhanced ultrasound (CEUS) with microbubble injection as an alternative adjunct technique for lymphatic mapping in lymphaticovenous anastomosis (LVA) surgery for genital lymphedema. A retrospective chart review approved by our institutional review board was performed for patients with genital lymphedema undergoing LVA surgery between 2020 and 2024. Intraoperative CEUS for lymphatic mapping was used with intradermal injection of microbubble suspension Lumason (Bracco Suisse, Monroe Township, NJ, USA). Data regarding demographics, comorbidities, clinical and operative characteristics, complications, and surgical outcomes were retrieved. Three patients with genital lymphedema who underwent LVA were identified. The first patient was a 34‐year‐old female with recurrent lymphangioma circumscriptum and vesicular drainage. She successfully underwent CEUS‐guided LVA followed by two debulking procedures. The second patient was a 16‐year‐old male with congenital scrotal and lower extremity lymphedema. He had two CEUS‐guided LVAs and subsequent debulking for anterior scrotal swelling, with long‐term reduction in edema. The third patient was a 31‐year‐old female with primary lymphedema of the right lower extremity and genital region. She underwent seven CEUS and indocyanine green lymphography (ICG) guided anastomoses targeting the mons and lower abdomen, resulting in substantial symptomatic and volumetric improvement. CEUS detected target lymphatic vessels in all cases, including cases where ICG imaging failed to identify candidate lymphatic vessels. CEUS with intradermal microbubble injection successfully identified target lymphatic vessels in the preoperative planning for LVA surgery in patients with genital lymphedema.
Role of long-chain acyl-CoA synthetases in MASH-driven hepatocellular carcinoma and ferroptosis
Classon, Peyton, Wixom, Alexander Q. , Mancipe, Natalia Calixto , Taner, Timuçin , Povero, Davide , Calixto Mancipe, Natalia , Tran, Nguyen , Povero, Davide , Wixom, Alexander Q , Graham, Rondell P. , Zhao, Yu , Tran, Nguyen H.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 28, 2025 | Volume: 329 | Issue: 5 | Pages: G571-G584

10.1152/ajpgi.00096.2025 | PMID 40875358 Get It

Our study examined healthy human MASH and MASH-associated hepatocellular carcinoma (MASH-HCC) livers using bulk and scRNA sequencing, spatial transcriptomics, and immunohistochemistry. We found that ACSLs displayed differential and spatially heterogeneous expression. ACSL4 was abundant in tumor tissues, whereas ACSL5 was elevated in noncancerous MASH tissues. ACSL4 was mainly found in immune cells like natural killer cells and natural killer T cells in murine MASH-HCC, suggesting its role in tumor immune microenvironment modulation.
Sex Differences in the Initiation and Progression of Necroptosis Following Kidney Ischemia–Reperfusion Injury
Tran, Minh H. , Parris, Colby L., Liu, Catherin, Oropeza, Andrea, Rani, Alka, Fan, Yingxiang, Fu, Liying , Buggs, Jacentha , Oropeza, Andrea, Esquivel, Carlos O. , Rani, Alka, Wang, Lei

Mayo Clinic

Biomedicines | August 27, 2025 | Volume: 13 | Issue: 9 | Pages: 2085

10.3390/biomedicines13092085 | PMID 41007648 Get It

Background: Ischemia–reperfusion injury (IRI) is a major contributor to acute kidney injury (AKI). While the precise mechanisms of AKI are still incompletely defined, extensive evidence highlights tubular cell injury and death as key factors in its development. Necroptosis has recently emerged as a critical pathway in the pathogenesis of ischemia–reperfusion-induced AKI (IR-AKI). Although sex differences in susceptibility to IR-AKI have been reported, it remains unclear whether there are sex differences in necroptosis dynamics and whether these differences underlie the observed sexual dimorphism in kidney IRI. This study aimed to address these questions. Methods: male and female C57BL/6 J mice were subjected to AKI via ischemia induced by bilateral renal pedicle clamping for 18 min at 37 °C. Plasma, urine, and kidney samples were collected at 0 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h post-reperfusion. Kidney injury and function were assessed by measuring plasma creatinine (PCr), blood urea nitrogen (BUN) levels, and histological damage (PAS and cleaved caspase3 staining). Necroptosis activation was assessed by quantifying phosphorylated forms of key markers: p-RIPK1 and p-MLKL. To explore the role of sex hormones in regulating necroptosis dynamics, ovariectomized female mice were subjected to the same IR-AKI protocol, and their kidney injury and functional outcomes were compared with those of intact counterparts. Results: The PCr was 0.35 ± 0.04 and 0.32 ± 0.06 mg/dL for males and females, respectively, at 3 h of IR. The levels exponentially increased to 2.05 ± 0.18 at 48 h post-reperfusion in the males but only gradually to 0.94 ± 0.13 mg/dL in females. Necroptosis activation began as early as 3 h post-IR in males but was delayed until ~6 h in females. Males exhibited stronger and more sustained necroptosis activation than females, showing elevated phosphorylation levels of pRIPK1 and pMLKL in Western blot. Female sex hormone deficiency exacerbated the female response to IR-induced injury, which reduced the sex difference in the dynamic of the necroptotic activation and subsequent kidney injury. To our knowledge, this is the first study to characterize sex differences in the initiation and progression of necroptosis and subsequent injury in a mouse model of IR-AKI. Conclusions: Our findings reveal distinct temporal patterns of programmed cell death between sexes. Necroptosis-targeted therapies require early intervention in males, which can be delayed in females after IR-AKI, highlighting the need for sex-specific therapeutic windows.
Validation of a Novel Patient-Reported Measure of The Burden of Digital Care in Diabetes
Zahidy, Misk Al, Maldonado, Kerly Guevara, Simha, Sue, Herzog, Alexandra, Hougen, Jada, Borras-Osorio, Mariana, Tran, Viet‐Thi , Guevara, Kerly , Branda, Megan E. , Ridgeway, Jennifer L. , Herzog, Alexandra, Hougen, Jada, Tran, Viet-Thi , Montori, Víctor M.

Mayo Clinic

No container title available | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7265768/v1 | PMID 40894032 Get It

Abstract Background Patients living with diabetes and chronic conditions may face significant burden managing their health. Many of these patients use digital medicine tools such as continuous glucose monitoring systems. Although measures exist to assess treatment burden from tasks such as managing medications and attending healthcare visits, there is no patient-reported measure that captures the burden of digital care. Therefore, the purpose of this study is to validate the Treatment Burden Questionnaire Plus Digital (TBQ + D), a patient-reported measure of treatment burden that includes using digital tools for adults with diabetes. Methods Adult patients with type 1 or type 2 diabetes mellitus completed the 25-item TBQ + D (scored 0 [none] to 10 [maximum] per item; total score range 0–250). We evaluated ease of administration, internal consistency, and tested hypotheses about the relationship between TBQ + D scores and treatment complexity, digital tool use intensity, social risk factors, and digital comfort to assess TBQ + D’s validity. Results Of 324 patients approached, 300 (93%) consented and completed the TBQ + D (mean age 57 [SD 17]; 50% female; 50% with type 2). The mean TBQ + D score was 53.7 (SD 41.6). Internal consistency was excellent (Cronbach’s α = 0.94). As hypothesized, higher TBQ + D scores were reported by patients with type 1 vs. type 2 diabetes mellitus (61.7 vs. 45.7; p = .0008), maximal/moderate vs. minimal to no digital tool use (56.5/60.7 vs. 41.3; p = .001), those on intensive insulin therapy vs. other treatments (61.4 vs. 38.0; p < .0001), and those with greater social vulnerability (p < .0106). TBQ + D scores were not significantly higher in patients with HbA1c ≥ 8% (p = .055) or less comfortable with digital technology (p = .08). Conclusions TBQ + D is a novel and valid measure of treatment burden in patients living with diabetes, inclusive of digital burden, that can play a role in fostering minimally disruptive care for patients with diabetes.
Application of Platelet-Rich Plasma in Gynaecologic Disorders: A Scoping Review
Willison, Nadia , Aryan, Pouria , Damabi, Negin Mirzaei, Nguyen, Tran , Yi, Johnny , Dutta, Rituparna, Aryan, Pouria , Padhani, Zahra Ali , Abbott, Derek , Behnia‐Willison, Fariba , Damabi, Negin Mirzaei, Dutta, Rituparna

Mayo Clinic

Journal of Clinical Medicine | August 18, 2025 | Volume: 14 | Issue: 16 | Pages: 5832

10.3390/jcm14165832 | PMID 40869658 Get It

Platelet-rich plasma (PRP) therapy is a non-invasive, autologous treatment with regenerative potential in gynaecology beyond fertility applications. This review evaluates PRP in non-fertility-related gynaecological conditions affecting women’s quality of life (QoL). Methods: Following PRISMA-ScR guidelines, we searched Embase, CINAHL, Web of Science, Scopus, CENTRAL, and MEDLINE for studies on PRP in conditions such as vulvar lichen sclerosus (VLS), vulvovaginal atrophy (VVA), sexual dysfunction (SD), stress urinary incontinence (SUI), and interstitial cystitis/bladder pain syndrome (IC/BPS). Of 3660 records screened, 43 studies (randomised controlled trials, quasi-experimental, cohort, and case series) were included. Results: PRP improved symptoms and QoL in several conditions, particularly VLS and SD, and was generally well tolerated with minor adverse effects (e.g., injection-site pain, transient discomfort). Evidence for abnormal uterine bleeding (AUB) and pelvic organ prolapse (POP) was inconclusive. Considerable heterogeneity in preparation protocols and outcome measures limited cross-study comparison. Conclusions: PRP shows promise as a minimally invasive therapy for certain gynaecological conditions. Standardisation of preparation and administration, along with large-scale RCTs, is needed to determine long-term efficacy and safety.
A Case Report of Symmetrical Drug‐Related Intertriginous and Flexural Exanthema‐Like Eruption Associated With Borrelial Infection
Espinoza, Elyana, Nguyen, A. , Tran, Tung S, Nguyen, Giang Huong , Tran, Tung S. , Nguyen, Alex V., Tran, Tung S , Nguyen, Giang H , Espinoza, Elyana, Nguyen, Alex V.

Mayo Clinic

Australasian Journal of Dermatology | August 7, 2025 | Volume: 66 | Issue: 7 | Pages: 433-435

10.1111/ajd.14570 | PMID 40772579 Get It

Comparative Evaluation of Contrast-enhanced Ultrasound and Indocyanine Green Lymphography for Lymphatic Mapping: A Retrospective Study
Jang, Samuel , Hesley, Gina K. , Lee, Christine U. , Tran, Nho V. , Fahradyan, Vahe , Rios, Maria, Fahradyan, Vahe , Bustos, Samyd S. , Rios, Maria

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | August 1, 2025 | Volume: 13 | Issue: 8 | Pages: e7022

10.1097/gox.0000000000007022 | PMID 40757387 Get It

Background: Lymphaticovenous anastomosis (LVA) is an effective surgical treatment for extremity lymphedema. Indocyanine green (ICG) fluorescent lymphography, the traditional standard for imaging lymphatic vessels, has limitations, including difficulty depicting deeper or congested lymphatics and contraindication in iodine hypersensitivity. This study evaluated contrast-enhanced ultrasound (CEUS) with microbubbles for identifying lymphatic vessels for LVA and compared it with ICG lymphography. Methods: In this single-center retrospective review, intraoperative CEUS with intradermal injection of microbubble suspension (Lumason, Bracco Diagnostics, Inc.) was used in patients before LVA surgery between October 2019 and February 2023. Pre- or intraoperative ICG lymphography was also used to identify target lymphatic vessels. All patients diagnosed with primary or secondary extremity lymphedema who underwent LVA were included. Technical success rate was defined as lymphatic vessels identified by CEUS that led to successful LVAs. Descriptive statistics were used. Results: Thirty-two patients underwent LVA surgery, with a mean age of 58.5 ± 13.9 years. CEUS identified lymphatic vessels in all 32 patients, including 7 in whom ICG failed. Two patients with ICG allergy underwent CEUS only. CEUS identified more candidate lymphatics per patient (5.3 ± 4.2) compared with ICG (2.5 ± 2.7). Of the 182 anastomoses, 96 (52.8%) were identified by both CEUS and ICG, 75 (41.2%) by CEUS only, and 11 (6%) by ICG only. Conclusions: CEUS is a promising tool for identifying lymphatic vessels in patients with lymphedema undergoing LVA, particularly when ICG lymphography is inadequate or contraindicated.
Implementation of Family-Based Treatment for Primary Care in a novel healthcare system: description of the adaptation process
Lau, Josephine S. , Kusumoputro, Sydney, Tran, Ann T., Fort, Victoria, Lee, Heather C., Pierce, Lindsey S., Timm, J., Yadav, Neha , Villarta, Michelle C., Lebow, Jocelyn , Tran, Ann T., Lee, Heather C., Pierce, Lindsey S., Timm, Jenna A., Lebow, Jocelyn

Mayo Clinic

Eating Disorders | July 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1080/10640266.2025.2524393 | PMID 40611545 Get It

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma
Breen, William G. , Anderson, S. Keith , Brown, Paul D. , Yan, Elizabeth , Kizilbash, Sani H. , Anderson, Daniel M. , Tran, David , Mazurczak, Miroslaw, Geoffroy, Francois J., Leinweber, Clinton, Dixon, Jesse G. , Anderson, S Keith , Yan, Elizabeth S, Kizilbash, Sani, Galanis, Eva, Kizilbash, Sani H , Sarkaria, Jann N. , Galanis, Evanthia , Tran, David D. , Johnson, Derek R. , Laack, Nadia N.

Mayo Clinic

Neuro-Oncology | June 27, 2025 | Volume: 27 | Issue: 10 | Pages: 2661-2670

10.1093/neuonc/noaf156 | PMID 40579995 Get It

Abstract Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the maximum tolerated dose (MTD), safety, and efficacy of dasatinib with radiation and temozolomide (TMZ) for glioblastoma. Following identification of the MTD, adult patients with a histologic diagnosis of glioblastoma were randomized 2:1 between dasatinib given with standard concurrent and adjuvant TMZ, versus placebo with standard concurrent and adjuvant TMZ. Radiation dose was 60 Gy in 30 fractions. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life. Results Thirteen patients were enrolled in the phase I component and established the MTD and phase II dose of 150 mg given daily. A total of 204 patients were enrolled in the phase II component. OS was not different between arms (median OS 15.6 months for dasatinib compared to 19.3 months for placebo, hazard ratio:1.21 favoring placebo, 95% CI: 0.88–1.65, log-rank P-value: .238). Similarly, PFS was not significantly different between the dasatinib and placebo arms. There was a significant increase in anemia, nausea, and creatinine elevation with dasatinib, but significantly more grade 3 lymphopenia with placebo. Conclusions The addition of dasatinib to standard chemoradiation did not improve outcomes for patients with glioblastoma. Clinical Trial Identifier NCT00869401.
A global real-world study assessing total time to adrenalectomy in primary aldosteronism
Ter, Charmaine , Koh, Xuan Han , Tran, Hieu , Araujo‐Castro, Marta , Boillos, Marga González , Gkaniatsa, Eleftheria , Reincke, Martín , Adolf, Christian, Tran, Thang Viet , Nayak, Drishya, Grytaas, Marianne Aardal , Matrozova, Joanna, Sukor, Norlela , Ismail, Farhana, Parasiliti‐Caprino, Mirko , Tsuiki, Mika , Ng, Chee Keng , Katabami, Takuyuki , St‐Jean, Matthieu , Saffari, Seyed Ehsan , Teo, Ada Ee Der , Bancos, Irina , Araujo-Castro, Marta , Gkaniatsa, Eleftheria , Reincke, Martin , Adolf, Christian , Stowasser, Michael , Turcu, Adina F , Sukor, Norlela , Kocjan, Tomaz , Parasiliti-Caprino, Mirko , Baudrand, Rene , Murakami, Masanori , Yang, Jun , Ng, Chrislyn , Katabami, Takuyuki , Naruse, Mitsuhide , St-Jean, Matthieu , Ceccato, Filippo , Saffari, Seyed Ehsan , Puar, Troy H , Bancos, Irina , Bassiony, Mohamed A. A. , Paja, Miguel , Stowasser, Michael , Nayak, Drishya, Grytaas, Marianne Aardal , Turcu, Adina F. , Ismail, Farhana, Kocjan, Tomaž , Baudrand, René , Uslar, Thomas , Murakami, Masanori , Yang, Jun , Ceccato, Filippo

Mayo Clinic

European Journal of Endocrinology | June 26, 2025 | Volume: 193 | Issue: 1 | Pages: 65-75

10.1093/ejendo/lvaf124 | PMID 40570195 Get It

Abstract Background Primary aldosteronism (PA) is a common treatable cause of hypertension. When caused by unilateral adrenal disease, it is potentially curable by adrenalectomy. However, specialized tests and other factors may delay definitive treatment. We assessed the time to adrenalectomy (TTA) for patients worldwide. Methods We conducted an international, multicentre retrospective study involving 39 centres from 15 countries to determine the total time taken from the first presentation to adrenalectomy and the intervals between each stage (screening, confirmatory, subtyping, and adrenalectomy). We included patients with PA who underwent adrenalectomy from January 1, 2018, to October 30, 2022. Post-adrenalectomy outcomes were evaluated using the Primary Aldosteronism Surgery Outcome criteria. We performed multivariable quantile and linear regression to identify characteristics associated with longer TTA. Results We included 861 patients, mean age 49.3 ± 11.1 years, and 44.5% were women. Overall median TTA was 13.5 months, IQR: 6.6-24.5. Median intervals were 0.1 months (screening), 1.0 months (confirmatory), 4.1 months (subtyping), and 4.3 months (adrenalectomy). On multivariable analysis, median TTA was increased by 5.4 months for each additional adrenal vein sampling (AVS) procedure. Other factors associated with longer TTA included adrenalectomy post-COVID-19, younger age, and additional screening tests. Compared with countries with routine AVS, those without AVS had a shorter TTA (6.1 vs 15.1 months, P &lt; .001), but greater likelihood of absent/partial biochemical success post-adrenalectomy (27.4% vs 12.4%, P &lt; .001). Conclusion Primary aldosteronism management is time-consuming worldwide, especially for subtyping tests and adrenalectomy. While omitting AVS reduces overall time, patients are less likely to achieve biochemical cure post-adrenalectomy.